Omecamtiv Mecarbil Not Ready for Prime Time, FDA Advisors Say

(MedPage Today) -- Omecamtiv mecarbil received a thumbs-down from FDA advisors who complained of its inadequate evidence base during a Cardiovascular and Renal Drugs Advisory Committee meeting on Tuesday. Members voted 8-3 (with no abstentions...
Source: MedPage Today Nephrology - Category: Urology & Nephrology Source Type: news